Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team

拥有深厚知识产权、临床阶段和纳斯达克上市公司经验的资深生物制药律师加入领导团队

SAN ANTONIO

圣安东尼奥

,

，

May 4, 2026

2026年5月4日

/PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq:

/PRNewswire/ -- Valion Bio, Inc.（前身为Tivic Health Systems, Inc.）（纳斯达克：

VBIO

VBIO

), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Ms. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built for Valion Bio's current phase of growth..

），一家临床阶段的免疫治疗公司，正在开发Entolimod™用于急性辐射综合症（ARS）和肿瘤支持治疗，今天宣布任命梅琳达·拉克为总法律顾问兼法律事务高级副总裁。拉克女士在临床阶段的生物制药开发、知识产权战略以及纳斯达克上市公司治理方面拥有近二十年的科学与法律综合经验，这一背景非常契合Valion Bio当前的成长阶段。

Ms. Lackey joins from Alaunos Therapeutics (Nasdaq:

拉克伊女士加入自阿拉努斯治疗公司（纳斯达克：

TCRT

TCRT

), a clinical trial-stage oncology cell therapy company, where she served as Senior Vice President of Legal & Administration. In that role, she managed all legal and compliance functions for the publicly traded immunology company, navigating complex clinical development, regulatory strategy, and capital markets obligations.

），这是一家处于临床试验阶段的肿瘤细胞治疗公司，她在那里担任法律与行政高级副总裁。在此职位上，她管理着这家上市免疫学公司的所有法律和合规职能，处理复杂的临床开发、监管策略和资本市场义务。

Prior to Alaunos, she served as Senior Legal Counsel at Kuur Therapeutics, a clinical trial-stage biopharmaceutical company focused on cellular immunotherapies, where she developed expertise in the legal architecture of next-generation immunological platforms..

在加入Alaunos之前，她曾在临床试验阶段的生物制药公司Kuur Therapeutics担任高级法律顾问，该公司专注于细胞免疫疗法，她在此期间积累了下一代免疫平台法律架构方面的专业知识。

Before transitioning in-house, Ms. Lackey was an associate at Winston & Strawn LLP and Howrey LLP, two firms with nationally recognized intellectual property and life sciences practices, where she built a strong foundation in patent litigation and prosecution, IP portfolio strategy, and biopharmaceutical transactions.

在转入公司内部之前，拉克女士曾是温斯顿律师事务所和豪瑞律师事务所的助理，这两家律所拥有全国知名的知识产权和生命科学业务实践，她在专利诉讼和申请、知识产权组合策略以及生物制药交易方面打下了坚实的基础。

Her legal training is further distinguished by an early career as a Research Associate at the University of Texas Health Science Center at Houston and a Research Technician at UT MD Anderson Cancer Center. She holds her J.D. from the University of Houston Law Center..

她的法律培训因早期在德克萨斯大学休斯顿健康科学中心担任研究助理以及在德克萨斯大学MD安德森癌症中心担任研究技术员而更加突出。她拥有休斯顿大学法律中心的法学博士学位。

The appointment comes as Valion Bio is in the process of advancing Entolimod™ toward an FDA Animal Rule approval pathway for ARS, and scaling its wholly owned CDMO subsidiary Velocity Bioworks in San Antonio. Ms. Lackey's transactional, IP, and public company governance experience positions her to support all of these workstreams simultaneously..

这项任命正值 Valion Bio 致力于推动 Entolimod™ 进入 FDA 动物规则审批路径以用于急性放射综合症 (ARS)，并扩展其全资拥有的 CDMO 子公司——位于圣安东尼奥的 Velocity Bioworks。Lackey 女士在交易、知识产权和上市公司治理方面的经验使她能够同时支持所有这些工作流程。

'Melinda's appointment reflects Valion Bio's direction. She has built her career at the intersection of cutting-edge immunotherapy and the legal strategy that protects it, from the bench at MD Anderson to senior legal leadership at a Nasdaq-listed cell therapy company. As we work to execute our capital raise, advance Entolimod™ through the Animal Rule pathway, and scale Velocity Bioworks, having an in-house General Counsel with her depth of scientific literacy, IP acumen, and public company experience is a strategic imperative,' said Michael K.

“梅琳达的任命反映了瓦利昂生物公司的发展方向。她的职业生涯建立在前沿免疫疗法与保护它的法律策略的交汇点上，从MD安德森的实验室到一家纳斯达克上市细胞治疗公司的高级法律领导职位。在我们努力执行融资、通过动物规则途径推进Entolimod™，以及扩大Velocity Bioworks规模的过程中，拥有一位具备她这样科学素养、知识产权敏锐度和上市公司经验的内部总法律顾问是战略上的当务之急，”迈克尔·K表示。

Handley, Chief Executive Officer of Valion Bio, Inc..

汉德利，瓦利昂生物公司首席执行官。

Ms. Lackey commented, 'I am excited to join Valion Bio at such a consequential moment in its evolution. The science behind Entolimod™ and Entolasta™ is compelling, and the combination of a clinical-stage pipeline, a government-aligned countermeasures program, and a fully operational CDMO subsidiary creates a legal environment that demands both precision and creativity.

拉克伊女士评论道：“我很高兴能在瓦利昂生物公司发展的关键时刻加入。Entolimod™和Entolasta™背后的科学非常引人注目，临床阶段的产品线、与政府一致的应对措施计划以及全资运营的CDMO子公司相结合，创造了一个既需要精确性又需要创造力的法律环境。”

I look forward to contributing to the company's mission of activating innate immunity to protect and extend life.'.

我期待为公司通过激活先天免疫来保护和延长生命的使命做出贡献。

About Valion Bio, Inc.

关于瓦利昂生物公司

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq:

瓦利昂生物公司（原名Tivic Health Systems公司）（纳斯达克：

VBIO

生物虚拟现实

) is a clinical-stage immunotherapeutics company developing Entolimod™, a TLR5 agonist, for Acute Radiation Syndrome (ARS) via the FDA Animal Rule pathway, oncology supportive care (neutropenia), and longevity indications. Entolimod™ has received Fast Track and Orphan Drug designations from the U.S.

）是一家临床阶段的免疫治疗公司，正在开发 Entolimod™——一种 TLR5 激动剂，用于通过 FDA 动物规则途径治疗急性放射综合症 (ARS)、肿瘤支持治疗（中性粒细胞减少症）和长寿相关适应症。Entolimod™ 已获得美国 FDA 的快速通道和孤儿药资格认定。

Food and Drug Administration. The company is also advancing Entolasta™, a next-generation TLR5 agonist. Valion Bio's wholly owned subsidiary, Velocity Bioworks (San Antonio, TX), is a full-service contract development and manufacturing organization (CDMO) offering biomanufacturing services to third-party biotech companies.

食品和药物管理局。该公司还正在推进Entolasta™，一种下一代TLR5激动剂。Valion Bio的全资子公司，位于德克萨斯州圣安东尼奥的Velocity Bioworks是一家全方位服务的合同开发和制造组织（CDMO），为第三方生物技术公司提供生物制造服务。

For more information, visit .

欲了解更多信息，请访问 。

www.valionbio.com

www.valionbio.com

.

。

Forward-Looking Statements

前瞻性声明

This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words.

本新闻稿可能包含“前瞻性陈述”，这些陈述受到重大风险和不确定性的影响。本新闻稿中除历史事实陈述之外的所有陈述均为前瞻性陈述。本新闻稿中的前瞻性陈述可以通过诸如“预期”、“相信”、“考虑”、“可能”、“估计”、“预计”、“意图”、“寻求”、“或许”、“也许”、“计划”、“潜力”、“预测”、“目标”、“瞄准”、“应该”、“将”、“会”等词语或这些词语的否定形式或其他类似表达来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other U.S.

前瞻性声明基于瓦利昂生物公司的当前预期，并受制于难以预测的固有不确定性、风险和假设。此外，某些前瞻性声明是基于对未来事件的假设，这些假设可能被证明不准确，包括由于公司与FDA和其他监管机构的互动及指导；BARDA和其他美国机构的持续关注。

government agencies in Entolimod™; the ability of the company to achieve the expected benefits from the acquisition of development and manufacturing assets within expected time frames or at all; changes to the company's relationship with its partners; failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations, including related to the Animal Rule; the company's future development of Entolimod or Entolasta; changes to the company's business strategy; timing and success of pre-clinical and clinical trials and study results; regulatory requirements and pathways for approval; the company's ability to successfully commerci.

政府机构对Entolimod™的影响；公司能否在预期时间内或完全实现从收购开发和制造资产中获得预期收益；公司与其合作伙伴关系的变化；未能获得FDA或类似许可或批准以及未遵守FDA或类似法规，包括与动物规则相关的规定；公司未来对Entolimod或Entolasta的开发；公司业务战略的调整；临床前和临床试验的时机与成功及研究结果；监管要求和审批路径；公司成功商业化的能力。

Investor Contact

投资者联系人

[email protected]

电子邮件地址

SOURCE Valion Bio, Inc.

来源：Valion Bio, Inc.

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示